| Name | Title | Contact Details |
|---|---|---|
Roan Martin |
Senior Director, R&D Quality | Profile |
Pauline Dufresne |
Vice President and Human Resources Business Partner | Profile |
JR Evans |
Director, Talent Acquisition | Profile |
Ronny Mosston |
Senior Vice President Human Resources | Profile |
Paula Ragan |
Chief Executive Officer | Profile |
Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are
Coastal Medical, Inc. is Rhode Islands largest, physician owned and physician governed Primary Care practice, serving patients in RI and southeastern Massachusetts.
Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
NLI offers: , Drug cGMP quality manufacturing processes , Superior laboratory support services following current Good Manufacturing Practices (cGMPs) , Disciplined and documented product design and engineering systems , Information-based customer